[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prime Medicine Inc (PRME)

Prime Medicine Inc (PRME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Prime Medicine Prepares to Report Another Loss Analysts Already Decided Not to Worry About

Prime Medicine (PRME) reports Q2 2026 earnings tomorrow, August 6, with analysts expecting a loss of $0.24 per share—a significant improvement from the $0.41 loss in the same quarter last year. The central question is whether the clinical-stage biotech can demonstrate meaningful progress in its gene editing pipeline while continuing to narrow losses, or if execution challenges will persist. With the stock trading at $3.08 and technical indicators flashing warning signs, the setup heading into this release is precarious.

Prime Medicine is a clinical-stage biotechnology company developing Prime Editing, a next-generation gene editing technology designed to correct genetic mutations with precision. The company focuses...

Fundamentals

See More
  • Market Capitalization, $K 556,300
  • Shares Outstanding, K 180,617
  • Annual Sales, $ 4,630 K
  • Annual Income, $ -201,140 K
  • EBIT $ -207 M
  • EBITDA $ -201 M
  • 60-Month Beta 2.31
  • Price/Sales 116.20
  • Price/Cash Flow N/A
  • Price/Book 7.02

Options Overview Details

View History
  • Implied Volatility 127.32% (+29.53%)
  • Historical Volatility 83.45%
  • IV Percentile 80%
  • IV Rank 54.91%
  • IV High 190.27% on 02/05/26
  • IV Low 50.65% on 05/20/26
  • Expected Move (DTE 15) 0.38 (12.34%)
  • Put/Call Vol Ratio 1.25
  • Today's Volume 447
  • Volume Avg (30-Day) 1,321
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 33,632
  • Open Int (30-Day) 32,617
  • Expected Range 2.72 to 3.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.24
  • Number of Estimates 6
  • High Estimate $-0.21
  • Low Estimate $-0.28
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) +41.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.72 +11.58%
on 08/03/26
4.82 -37.10%
on 07/08/26
-0.95 (-23.93%)
since 07/06/26
3-Month
2.67 +13.67%
on 06/11/26
4.82 -37.10%
on 07/08/26
-0.38 (-11.00%)
since 05/06/26
52-Week
2.67 +13.67%
on 06/11/26
6.94 -56.27%
on 10/06/25
-1.04 (-25.43%)
since 08/06/25

Most Recent Stories

More News
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 ...

PRME : 2.98 (-3.25%)
Prime Medicine Prepares to Report Another Loss Analysts Already Decided Not to Worry About

Barchart Research What to Expect from PRME Earnings PRME Generated August 5, 2026 Current Price $3.08 EPS Estimate $$-0.24 Consensus Rating Strong Buy Average Move 6.16% Prime Medicine Prepares to Report...

PRME : 2.98 (-3.25%)
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most...

PRME : 2.98 (-3.25%)
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

-- Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary...

PRME : 2.98 (-3.25%)
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47...

PRME : 2.98 (-3.25%)
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America...

PRME : 2.98 (-3.25%)
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 2.98 (-3.25%)
Prime Medicine to Present at Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 2.98 (-3.25%)
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 --   -- Continued regulatory...

PRME : 2.98 (-3.25%)
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 2.98 (-3.25%)

Business Summary

Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 3.40
2nd Resistance Point 3.26
1st Resistance Point 3.17
Last Price 2.98
1st Support Level 2.94
2nd Support Level 2.80
3rd Support Level 2.71

See More

52-Week High 6.94
Fibonacci 61.8% 5.31
Fibonacci 50% 4.81
Fibonacci 38.2% 4.30
Last Price 2.98
52-Week Low 2.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.